An observational study in Non Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-05.
Sponsored by Rigshospitalet, Denmark · Observational
The study examines the physical capacity of lung cancer patients assessed with the six minute walk test and handgrip strength. Demographic and selfreported exercise behavior is registered to explore correlations to functional and physical capacity.
Assessments are made before first chemotherapy cycle and after fourth chemotherapy cycle, an expected average of 12 weeks between first and second assessment.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 80 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Non Small Cell Lung Cancer Stage Small Cell Lung Cancer
Exclusion Criteria:
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Mortality - Survival time
Prognostic value of the six minute walk and handgrip strength on mortality
Time frame: time from first chemotherapy treatment to death, assessed after 30 months
Hand grip strength
Time frame: before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.
Self reported exercise behavior
Time frame: before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.
Six minute walk test
Time frame: Before first and after fourth chemotheraphy cycle, an expected average of 12 weeks between first and second assessment.
FACT-L
Patient reported outcome
Time frame: Before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rigshospitalet, Denmark